{
  "abstract": "Background and Importance Tezepelumab blocks thymic stromal lymphopoietin and reduces severe asthma exacerbations across phenotypes. Real-world data help quantify effectiveness in routine practice.Aim and Objectives To assess changes in oral corticosteroid (OCS)–treated exacerbations and hospitalisations during the first year after tezepelumab initiation in clinical practice.Material and Methods Retrospective, single-centre cohort of adults who initiated tezepelumab from November 2023 to September 2025. Demographics, dispensing dates, line of biologic therapy, glucocorticoid-treated exacerbations, identified by pharmacy prescription-claim refills for oral corticosteroid (OCS) bursts in the year before and the first year after initiation, and asthma-related hospitalisations were extracted from electronic records. Within-patient pre/post comparisons were summarised overall and in a predefined subgroup with ≥12 months’ follow-up.Results Fifty-one patients were included (mean age 58.5±13.2 years; 62.7% male). Tezepelumab was used as first-line in 25/52 (48.1%), second-line in 15/52 (28.8%), and third-line or later in 12/52 (23.1%). Median time of treatment prescription was 12.6 months (IQR 4–17.2).Overall (paired n=51), the annualised OCS-treated exacerbations rate decreased from 2 to 0.49 events/patient-year (naïve rate ratio [RR] 0.25). Among those with ≥12 months’ follow-up (n=22), OCS-treated exacerbations fell from 1.5 to 0.41 (RR 0.27). After one year, 68.6% had zero OCS-treated exacerbations and 84.1% achieved ≥50% reduction. Hospitalisations (mean per patient over each 1-year window) were 0.52 before vs 0.19 after overall; in the ≥12-month subgroup, 0.23 before vs 0.05 after. Thirteen patients (25.0%) discontinued tezepelumab; 7/52 (13.5%) initiated another biologic –omalizumab (n=3), dupilumab (n=2), mepolizumab (n=1), and benralizumab (n=1). One death unrelated to tezepelumab occurred during follow-up.Conclusion and Relevance In this single-centre cohort, tezepelumab was associated with substantial reductions in OCS-treated exacerbations during the first treatment year and with concurrent decreases in asthma-related hospitalisations, with effects evident among patients followed for ≥12 months. Larger, multicentre studies with longer follow-up are warranted.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital Universitario Jerez De La Frontera, Pharmacy, Jerez-Cádiz, Spain"
      ],
      "name": "N Báez"
    },
    {
      "affiliations": [
        "Hospital Universitario Jerez De La Frontera, Pharmacy, Jerez-Cádiz, Spain"
      ],
      "name": "M Nuñez García"
    },
    {
      "affiliations": [
        "Hospital Universitario Jerez De La Frontera, Pharmacy, Jerez-Cádiz, Spain"
      ],
      "name": "H Rodríguez Ramallo"
    },
    {
      "affiliations": [
        "Hospital Universitario Jerez De La Frontera, Pharmacy, Jerez-Cádiz, Spain"
      ],
      "name": "M González Martínez"
    },
    {
      "affiliations": [
        "Hospital Universitario Jerez De La Frontera, Pharmacy, Jerez-Cádiz, Spain"
      ],
      "name": "JF Sierra Sánchez"
    }
  ],
  "title": "4CPS-319 Impact of tezepelumab on oral corticosteroid–treated exacerbations and hospitalisations in severe asthma: real-world single-centre data",
  "uid": "f078716a-32f9-5a0a-bc97-22233c3763de"
}